(Q35919150)

11 August 2017

1 reference

title

Therapy of autoimmune bullous diseases (English)

1 reference

11 August 2017

Diya F Mutasim

1

1 reference

11 August 2017

1 March 2007

1 reference

Therapeutics and Clinical Risk Management

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

1

1 reference

11 August 2017

29-40

1 reference

Management of autoimmune bullous diseases: pharmacology and therapeutics

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

DEMONSTRATION OF SKIN ANTIBODIES IN SERA OF PEMPHIGUS VULGARIS PATIENTS BY INDIRECT IMMUNOFLUORESCENT STAINING.

11 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

11 July 2018

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of pemphigus vulgaris and pemphigus foliaceus with mycophenolate mofetil

31 March 2020

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Guidelines for the management of bullous pemphigoid

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Epidermolysis bullosa acquisita responsive to dapsone therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

A systematic review of treatments for bullous pemphigoid

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Immunofluorescence in dermatology.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Current therapy of pemphigus vulgaris

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Emerging treatment for epidermolysis bullosa acquisita

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

End of the century overview of skin blisters

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Immunoablative high-dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

A major role for neutrophils in experimental bullous pemphigoid.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Nonscarring inflammatory epidermolysis bullosa acquisita with esophageal involvement and linear IgG deposits.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

The adjuvant therapy of pemphigus. An update

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Paraneoplastic pemphigus: a case of prolonged survival

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Nicotinamide and tetracycline therapy of bullous pemphigoid.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Adjuvant Therapy of Pemphigus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Azathioprine for pemphigus and pemphigoid--a 4 year follow-up

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Dapsone therapy of cicatricial pemphigoid.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Oral gold therapy (Auranofin) in pemphigus vulgaris

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Clearing of epidermolysis bullosa acquisita with cyclosporine.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Dapsone as first line therapy for bullous pemphigoid.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Intractable epidermolysis bullosa acquisita: efficacy of cyclosporin A.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Prolonged remission after cyclosporine therapy in pemphigus vulgaris: report of two young siblings.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

The use of chlorambucil in the treatment of bullous pemphigoid

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Bullous and cicatricial pemphigoid

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Dapsone therapy for the acute inflammatory phase of ocular pemphigoid

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Paraneoplastic pemphigus with autoantibody deposition in bronchial epithelium after autologous bone marrow transplantation

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Pemphigus foliaceus. Use of antimalarial agents as adjuvant therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Bullous pemphigoid:therapy in patients with and without diabetes mellitus

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Benign mucous membrane pemphigoid. Response to therapy with cyclophosphamide

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Bullous Pemphigoid Responding to Sulfapyridine and the Sulfones

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody).

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

A comparison of oral and topical corticosteroids in patients with bullous pemphigoid

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Colchicine for epidermolysis bullosa acquisita

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1936286

Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease

24 September 2018

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of nine cases of pemphigus vulgaris with cyclosporine

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Dapsone as initial treatment in superficial pemphigus. Report of nine cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Mycophenolate mofetil monotherapy for pemphigus vulgaris

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of pemphigus with intravenous immunoglobulin

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Epidermolysis bullosa acquisita--a case with upper airways obstruction requiring tracheostomy and responding to cyclosporin

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of epidermolysis bullosa acquisita with cyclosporine

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Azathioprine in the treatment of muco-cutaneous pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Paraneoplastic pemphigus associated with Hodgkin's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

The treatment of mild pemphigus vulgaris and pemphigus foliaceus with a topical corticosteroid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of pemphigus vulgaris with mycophenolate mofetil

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Plasmapheresis therapy for bullous pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Systemic steroids and eczematized Darier's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Azathioprine in Treatment of Bullous Pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Controlled study of plasma exchange in pemphigus

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Paraneoplastic pemphigus: potential therapeutic effect of plasmapheresis

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

When and how to use sulfones in bullous diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Clear-cell carcinoma of the lung in a patient treated with cyclosporine for epidermolysis bullosa acquisita

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Cyclophosphamide in the treatment of pemphigus vulgaris and bullous pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Clearing of epidermolysis bullosa acquisita with cyclosporine

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Juvenile pemphigus foliaceous: response to dapsone

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Gluten Challenge in Dermatitis Herpetiformis

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Epidermolysis bullosa acquisita--successful treatment with colchicine

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Remission of severe epidermolysis bullosa acquisita induced by extracorporeal photochemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment considerations while awaiting the ideal bullous pemphigoid trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Successful therapy for bullous pemphigoid with mycophenolate mofetil

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Mycophenolate mofetil in autoimmune and inflammatory skin disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of pemphigus with gold

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Minimizing cicatricial pemphigoid orodynia with minocycline

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Pemphigus vulgaris: results of treatment with gold as a steroid-sparing agent in a series of thirteen patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Immunomorphologic and biochemical identification of the pemphigus foliaceous autoantigen within desmosomes

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Plasma exchange in bullous pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Immunoapheresis in paraneoplastic pemphigus

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of dermatitis herpetiformis with cholestyramine

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

High-dose methylprednisolone in the treatment of bullous pemphigoid

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of dermatitis herpetiformis with colchicine

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Methotrexate as an adjuvant treatment for pemphigus vulgaris

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Paraneoplastic pemphigus: a case with high titer of circulating anti-basement membrane zone autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Effects of cyclosporin on bullous pemphigoid and pemphigus

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of generalized bullous pemphigoid with oral tetracycline

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

Cyclosporine A in epidermolysis bullosa acquisita

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FTCRM.2007.3.1.29

An eruption secondary to intravenous immunoglobulin therapy

31 March 2020

1 reference

12 December 2020

Mycophenolate is effective in the treatment of pemphigus vulgaris

1 reference

12 December 2020

[Value of colchicine in treating acquired epidermolysis bullosa]

1 reference

12 December 2020

Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus

1 reference

12 December 2020

Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus

1 reference

12 December 2020

Dapsone for the treatment of bullous pemphigoid

1 reference

12 December 2020

Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita

1 reference

12 December 2020

Paraneoplastic pemphigus

1 reference

12 December 2020

Tetracycline and niacinamide: treatment alternatives in ocular cicatricial pemphigoid

1 reference

12 December 2020

Epidermolysis bullosa acquisita, a rare late complication of allogeneic bone marrow transplantation?

1 reference

12 December 2020

Identifiers

DOI

10.2147/TCRM.2007.3.1.29

1 reference

11 August 2017

1 reference

PMC publication ID

1936286

11 August 2017

PubMed publication ID

18360613

1 reference

PMC publication ID

1936286